Table 2

 Evaluation of the treatment symptomatic efficacy between groups: changes between baseline and final visit. Intention to treat analysis with the last observation carried forward

Changes between baseline and final visit (n = 301)NRD101 (n = 131)Diacerein (n = 85)Placebo (n = 85)Analysis of variance (p value)
Results are shown as mean (SD).
*For change assessment, the 0–24 Lequesne’s index has been translated into a 0–100 scale.
Pain (0–100 VAS)−33.5 (28.5)−33.9 (25.7)−34.5 (27.4)0.96
Lequesne’s algofunctional index*−20.0 (16.5)−18.8 (14.7)−18.9 (16.9)0.84
Patient’s global assessment (0–100 VAS)−29.7 (26.9)−32.8 (24.0)−31.1 (31.7)0.82
Percentage of painful days (0–100 VAS)−43.5 (40.3)−45.6 (37.8)46.6 (37.2)0.83